Publications by authors named "J Morganroth"
Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.
Neurol Clin Pract
February 2025
Background: The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.
Recent Findings: There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.
Background And Objectives: In 2016, a randomized controlled trial demonstrated the clinical efficacy of trans-sternal thymectomy for patients with non-thymomatous myasthenia gravis (MG). Whether large-scale changes occurred in clinical practice after this trial is unknown.
Methods: We performed a retrospective longitudinal cross-sectional analysis using National Inpatient Sample (NIS) data from 2012 to 2019.
Article Synopsis
- Qalsody (tofersen), an intrathecal therapy for ALS, received FDA accelerated approval on April 25, 2023, requiring academic centers to plan for quick drug delivery.
- The model predicted our center would see 6 symptomatic and 14 presymptomatic ALS patients post-approval, but a hypothetical sporadic ALS therapy could increase that number to 108 patients.
- With the introduction of new neurological therapies, it's crucial for healthcare providers to prepare for a rise in patient visits and the complexities of administering these treatments effectively.
Delamanid and bedaquiline are two drugs approved to treat drug-resistant tuberculosis, and each have been associated with corrected QT interval (QTc) prolongation. We aimed to investigate the relationships between the drugs' plasma concentrations and the prolongation of observed QT interval corrected using Fridericia's formula (QTcF) and to evaluate their combined effects on QTcF, using a model-based population approach. Furthermore, we predicted the safety profiles of once daily regimens.
View Article and Find Full Text PDF